(Q38350089)

2 September 2017

1 reference

title

Are androgen receptor variants a substitute for the full-length receptor? (English)

1 reference

2 September 2017

Ji Lu

1

1 reference

2 September 2017

Travis Van der Steen

series ordinal

2

1 reference

2 September 2017

Donald J Tindall

series ordinal

3

1 reference

2 September 2017

language of work or name

English

0 references

publication date

10 February 2015

1 reference

2 September 2017

published in

Nature Reviews Urology

1 reference

2 September 2017

volume

12

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

137-144

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2015.13

2 September 2017

exact match

0 references

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Steroid hormone receptors in prostate cancer: a hard habit to break?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Mechanisms of androgen-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Androgen receptor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

The androgen receptor gene mutations database: 2012 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Contribution of the androgen receptor to prostate cancer predisposition and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Posttranslational modification of the androgen receptor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Nuclear receptor structure: implications for function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Alternatively spliced androgen receptor variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Mechanisms of the androgen receptor splicing in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

The role of epithelial plasticity in prostate cancer dissemination and treatment resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Androgen receptor splice variants determine taxane sensitivity in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Androgen receptor coregulators and their involvement in the development and progression of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

The role of DAB2IP in androgen receptor activation during prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signaling in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.13

IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25666893

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25666893

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Shortened isoforms of the androgen receptor are regulated by the cytoprotective heat-shock protein HSPB1 and the tumor-suppressive microRNA miR-1 in prostate cancer cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25666893

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRUROL.2015.13

1 reference

Dimensions Publication ID

2 September 2017

1005325657

0 references

1 reference